CLOUDBREAK-B (02592) surged more than 4%, reaching HK$8.58 by the time of writing, with a trading volume of HK$11.82 million. The company announced that its wholly-owned U.S. subsidiary, Cloudbreak USA, has scheduled a post-Phase 2 clinical trial meeting with the U.S. Food and Drug Administration (FDA) on December 10, 2025. The meeting will focus on the clinical-stage drug candidate CBT-004.

This post-Phase 2 meeting marks a critical milestone in CBT-004's development, as it will discuss potential Phase 3 clinical trial plans and requirements for a New Drug Application (NDA).